News

Medarex expects to receive an undisclosed milestone payment from its licensee, Bristol-Myers for the advancement into clinical trials of BMS-66513, a fully human antibody that targets CD137, for

The dose-escalating, safety and tolerability study of the drug will be conducted at multiple sites in Australia and undertaken under both US and Australian regulatory authorizations. Xenome has

The grant will support preclinical studies to determine the optimal Oxiplex gel for injectable delivery of a bone growth peptide, and to evaluate the efficacy of the peptide

Azithromycin is the AB-rated generic equivalent of Pfizer’s Zithromax, an antibiotic indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of bacteria.

The preventive HIV vaccine candidate, tgAAC09, utilizes a recombinant adeno-associated viral vector (rAAV) that was developed with and manufactured by Targeted Genetics Corporation. Under the terms of a

One-year survival was 88% and two-year survival was 76%, with a mean follow-up of approximately 24 months. These results compare favorably with historical data from multiple studies in

Building on successful data derived from its proprietary in vitro models of the disease, Synairgen is investigating a novel application of inhaled interferon-Beta (IFN-Beta) to reduce asthma exacerbations

Acute coronary syndromes (ACS) account for more than one million hospitalizations annually in the US. ACS occurs when an atherosclerotic plaque ruptures in a coronary artery, triggering the

The drug, which is a serotonin 4 (5-HT4) receptor agonist, was also well-tolerated in the trial. The company now expects to initiate a phase II dose-ranging trial in